Associated Banc Corp Has $39.71 Million Holdings in IQVIA Holdings Inc. $IQV

Associated Banc Corp grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 3.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 176,163 shares of the medical research company’s stock after purchasing an additional 5,205 shares during the period. IQVIA comprises approximately 1.0% of Associated Banc Corp’s investment portfolio, making the stock its 24th biggest holding. Associated Banc Corp’s holdings in IQVIA were worth $39,709,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in IQV. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA in the fourth quarter valued at $25,000. Physician Wealth Advisors Inc. grew its stake in shares of IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares in the last quarter. International Assets Investment Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at $27,000. Westside Investment Management Inc. grew its stake in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new position in shares of IQVIA in the third quarter valued at $30,000. 89.62% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on IQV shares. Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Mizuho set a $215.00 price objective on shares of IQVIA in a research report on Monday, February 23rd. Evercore reaffirmed an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. Finally, Royal Bank Of Canada began coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $225.69.

IQVIA Trading Up 0.2%

Shares of IQVIA stock opened at $168.28 on Friday. The firm has a 50-day moving average of $169.72 and a 200-day moving average of $197.56. The stock has a market cap of $28.09 billion, a PE ratio of 20.85, a PEG ratio of 1.61 and a beta of 1.18. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has approved a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.